Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 409-414

  Weisenberg, Judith L Z ^a   Wong, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drug; Epilepsy; Ezogabine

Indexed keywords

LAMOTRIGINE; PLACEBO; RETIGABINE;

ADJUVANT THERAPY; AMNESIA; ANTICONVULSANT ACTIVITY; ARTICLE; ASTHENIA; ATAXIA; BENIGN CHILDHOOD EPILEPSY; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSARTHRIA; FATIGUE; FOCAL EPILEPSY; GENE MUTATION; HEADACHE; HUMAN; MAINTENANCE DRUG DOSE; NAUSEA; NONHUMAN; SOMNOLENCE; SPEECH DISORDER; THOUGHT DISORDER; TREMOR; URINARY TRACT INFECTION; URINE RETENTION; VERTIGO;

EID: 80053645719     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology. 2011;76:23-27.
2. Zarrelli MM, Beghi E, Rocca WA, Hauser WA. Incidence of epileptic syndromes in Rochester, Minnesota. Epilepsia. 1999;40:1708-1714.
3. Forsgren L, Hauser WA, Olafsson E, Sander JWAS, Sillanpaa M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia. 2005;46(Suppl 11):18-27.
4. Strine TW, Kobau R, Chapman DP, Thurman DJ, Price P, Balluz LS. Psychological distress, comorbidities, and health behaviors among U S adults with seizures: results from the 2002 national health interview survey. Epilepsia. 2005;46:1133-1139.
5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
6. Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localizationrelated epilepsies. Seizure. 2005;14:318-323.
7. Rundfelt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol. 1997;336:243-249.
8. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000;58:591-600.
9. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000;58:253-262.
10. Schenzer A, Friedrich T, Pusch M, et al. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci. 2005;25:5051-5060.
11. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67:1009-1017.
12. Lange W, Geissendorfer J, Schenzer A, et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol. 2009;75:272-280.
13. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett. 2000;282:73-76.
14. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci. 2001;21:5535-5545.
15. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung.2000;50:1063-1070.
16. van Rijn CM, Willems-van Bree E. Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol. 2003;464:95-100.
17. Rostock A, Tober C, Rundfeldt C, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23:211-223.
18. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naynyn Schmiedebergs Arch Pharmacol. 2001;363:330-336.
19. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia. 2008;49:1777-1786.
20. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science. 1998;279:403-406.
21. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet. 1998;18:53-55.
22. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18:25-29.
23. Porter RJ, Partiot A, Sachedo R, Nohria C, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197-1204.
24. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75:1817-1824.
25. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, doubleblind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76:1555-1563.
26. Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol. 2004;172:2054-2058.
27. Rode F, Svalo J, Sheykhzade M, Ronn LCB. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol. 2010;638:121-127.
28. McNeilly RJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM. In vitro glucuronidation of D-23129, a novel anticonvulsant, by human liver microsomes and liver slices. Xenobiotica. 1997;27:431-441.
29. Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos. 1999;27: 613-622.
30. Hiller A, Nguyen N, Strassburg C, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999;27:605-612.
31. Borlak J, Gasparic A, Locher M, Schupke H, Hermann R. N-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler Najjar type II. Metabolism. 2006;5:711-721.
32. Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, doseproprotional, pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol. 2002;42:175-182.
33. Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther. 2003;73:61-70.
34. Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58:795-802.
35. Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol. 2003;56:39-45.
36. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83:1-43.
37. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38:714-722.
38. Auger RG, Daube JR, Gomez MR, Lambert EH. Hereditary form of sustained muscle activity of peripheral nerve origin causing generalized myokymia and muscle stiffness. Ann Neurol. 1984:15:13-21.
39. Dedek K, Kunath B, Kananura C, Reuner U, Jentsch TJ, Steinlein OK. Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc Natl Acad Sci U S A. 2001;98:12272-12277.
40. Wuttke TV, Jurkat-Rott K, Paulus W, Garnkarek M, Lehrman-Horn F, Lerche H. Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology. 2007;69:2045-2053.
41. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviors in rat models of persistent and neuropathic pain. Eur J Pharmacol. 2003;460:109-116.
42. Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology. 2007;53:609-618.
43. Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav. 2008;12:49-53.
44. Hansen HH, Andreasen JT, Weikop P, Mirza M, Scheel-Kruger J, Mikkelsen JD. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol. 2007;570:77-88.
45. Richter A, Sander SE, Rundfelt C. Antidystonic effects of Kv7 (KCNQ) channel openers in the dtsz mutant, an animal model of primary paroxysmal dystonia. Br J Pharmacol. 2006;149:747-753.
46. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther. 2005; 314:282-292.